Patents by Inventor B. Nelson Chau

B. Nelson Chau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20240141350
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: November 30, 2023
    Publication date: May 2, 2024
    Applicants: Regulus Therapeutics Inc., The Board of Regents of The University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20220380767
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: July 22, 2022
    Publication date: December 1, 2022
    Applicants: Regulus Therapeutics Inc., The Board of Regents of The University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • MONITORING GENE THERAPY
    Publication number: 20220308070
    Abstract: The present disclosure provides, among other things, technologies for improving gene therapy. Among other things, the present disclosure provides technologies that permit monitoring and/or assessment one or more characteristics of a gene therapy treatment such as, for example, extent, level, and/or persistence of payload expression. In some embodiments, provided technologies particularly useful with integrating gene therapy.
    Type: Application
    Filed: April 14, 2020
    Publication date: September 29, 2022
    Inventors: B. Nelson Chau, Jing Liao, Susana Gordo
  • NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA
    Publication number: 20220218843
    Abstract: Methods and technologies for the treatment of methylmalonic acidemia.
    Type: Application
    Filed: October 30, 2018
    Publication date: July 14, 2022
    Applicant: LogicBio Therapeutics, Inc.
    Inventors: Charles P. Venditti, Randy J. Chandler, B. Nelson Chau, Kyle P. Chiang, Jing Liao
  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20220213483
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Applicants: Regulus Therapeutics Inc., The Board of Regents of The University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20220025372
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Applicants: Regulus Therapeutics Inc., Board of Regents of The University of Texas System
    Inventors: John R. ANDROSAVICH, B. Nelson CHAU, Vishal D. PATEL
  • Methods for treatment of polycystic kidney disease
    Patent number: 11168325
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: November 9, 2021
    Assignees: Regulus Therapeutics Inc., Board of Regents of The University of Texas System
    Inventors: John R. Androsavich, B. Nelson Chau, Vishal D. Patel
  • METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20200392503
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 17, 2020
    Applicants: Regulus Therapeutics Inc., The Board of Regents of the University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20200392501
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 17, 2020
    Applicants: Regulus Therapeutics Inc., The Board of Regents of the University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20200231971
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 23, 2020
    Applicants: Regulus Therapeutics Inc., Board of Regents of the University of Texas System
    Inventors: John R. ANDROSAVICH, B. Nelson CHAU, Vishal D. PATEL
  • Methods for treatment of polycystic kidney disease
    Patent number: 10633657
    Abstract: Provided herein are methods for the treatment of poly-cystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: April 28, 2020
    Assignees: Regulus Therapeutics Inc., Board of Regents of the University of Texas System
    Inventors: John R. Androsavich, B. Nelson Chau, Vishal D. Patel
  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20190345494
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: December 4, 2017
    Publication date: November 14, 2019
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20190153442
    Abstract: Provided herein are methods for the treatment of poly-cystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: August 25, 2016
    Publication date: May 23, 2019
    Applicants: Regulus Therapeutics Inc., Board of Regents of the University of Texas System
    Inventors: John R. Androsavich, B. Nelson Chau, Vishal D. Patel
  • METHODS FOR DIRECT MEASUREMENT OF MICRORNA INHIBITION AND MIMICRY
    Publication number: 20180363056
    Abstract: The disclosure includes methods of determining the activity of an inhibitor of a target microRNA (miRNA) or of a mimic of a target microRNA. Determination of polysome occupancy in treated and control samples followed by comparing the occupancies can be used to determine a displacement value for the inhibitor or mimic of the target miRNA. The displacement value reflects the extent of a change in the levels of the target miRNA (which may include the mimic if applicable) in polysomal and non-polysomal compartments of a sample or a shift of the target miRNA between polysomal and non-polysomal compartments of a sample and can indicate the activity of the inhibitor toward the target miRNA or of the mimic toward a target RNA.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 20, 2018
    Applicant: Regulus Therapeutics Inc.
    Inventors: John R. Androsavich, B. Nelson Chau, Ryan R. Galasso
  • Targeting MicroRNAs for the Treatment of Fibrosis
    Publication number: 20180305690
    Abstract: Provided herein are compositions and methods for the modulation of miR-214 for the treatment and/or prevention of fibrosis and fibroproliferative conditions.
    Type: Application
    Filed: April 16, 2018
    Publication date: October 25, 2018
    Applicant: Regulus Therapeutics Inc.
    Inventor: B. Nelson Chau
  • Targeting microRNAs for the treatment of fibrosis
    Patent number: 9970007
    Abstract: Provided herein are compositions and methods for the modulation of miR-214 for the treatment and/or prevention of fibrosis and fibroproliferative conditions.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 15, 2018
    Assignee: Regulus Therapeutics Inc.
    Inventor: B. Nelson Chau
  • TARGETING MICRORNAS FOR THE TREATMENT OF FIBROSIS
    Publication number: 20170198289
    Abstract: Provided herein are compositions and methods for the modulation of miR-214 for the treatment and/or prevention of fibrosis and fibroproliferative conditions.
    Type: Application
    Filed: December 15, 2016
    Publication date: July 13, 2017
    Applicant: Regulus Therapeutics Inc.
    Inventor: B. Nelson Chau
  • Targeting microRNAs for the treatment of fibrosis
    Patent number: 9556435
    Abstract: Provided herein are compositions and methods for the modulation of miR-214 for the treatment and/or prevention of fibrosis and fibroproliferative conditions.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: January 31, 2017
    Assignee: Regulus Therapeutics Inc.
    Inventor: B. Nelson Chau
  • TARGETING MICRORNAS FOR THE TREATMENT OF FIBROSIS
    Publication number: 20160108397
    Abstract: Provided herein are compositions and methods for the modulation of miR-214 for the treatment and/or prevention of fibrosis and fibroproliferative conditions.
    Type: Application
    Filed: October 1, 2015
    Publication date: April 21, 2016
    Inventor: B. Nelson Chau
  • Targeting micrornas for the treatment of fibrosis
    Patent number: 9181548
    Abstract: Provided herein are compositions and methods for the modulation of miR-214 for the treatment and/or prevention of fibrosis and fibroproliferative conditions.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: November 10, 2015
    Assignee: REGULUS THERAPEUTICS INC.
    Inventor: B. Nelson Chau